



ABT-751

Catalog No: tcsc0495



Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

141430-65-1

Formula:

 $C_{18}H_{17}N_3O_4S$

Pathway:

Cell Cycle/DNA Damage; Cytoskeleton; Autophagy

Target:

Microtubule/Tubulin; Microtubule/Tubulin; Autophagy

Purity / Grade:

>98%

Solubility:

DMSO : \geq 48 mg/mL (129.24 mM)

Alternative Names:

E7010

Observed Molecular Weight:

371.41

Product Description





ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 μ M in neuroblastoma and non-neuroblastoma cell lines, respectively.

IC50 Value: 1.5 μM(neuroblastoma); 3.4 μM(non-neuroblastoma)

Target: Microtubule/Tubulin

in vitro: ABT-751 shows the selective cytotoxicity with IC50 of $0.6-2.6~\mu M$ in neuroblastoma and $0.7-4.6~\mu M$ in other solid tumor cell lines. Furthermore, ABT-751 also exhibits a selective effect on dynamic microtubules and spares stable microtubules, accounting for the persistence of acetylated and detyrosinated α -tubulin positive polymerized tubules at the IC90 concentration of ABT-751.

in vivo: In Calu-6 xenograft model, ABT-751 as a single agent at 100 and 75 mg/kg/day shows significant antitumor activity, while in combination with cisplatin, ABT-751 shows a dose-dependent enhancement in growth delay. In the HT-29 colon xenograft model, ABT-751 also shows significant antitumor activity as a single agent and produced a dose-dependent enhancement in growth delay In combination with 5-FU. In dogs with lymphoma, ABT-751 exhibits the dose-limiting toxicities that included vomiting, diarrhea, anorexia, or some combination of these with a maximum tolerated dose (MTD) of 350 mg/m2 PO q24h. Furthermore, the mean AUC and Cmax for ABT-751 at the MTD of 350 mg/m2 is 5.55 µg-hour/mL and 0.9 µg/mL, respectively.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!